CharlesJLinkJr.MDFACP

Internal Medicine • Austin, TX

Hematology/Oncology

Executive Chairman Syncromune, Inc

Join to view full profile

Dr. Link is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Link's full profile

Already have an account?

Office
.
Austin, TX 78701
Is this information wrong?

Summary

immuno-oncology

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1988 - 1992
University of California (San Francisco)Residency, Internal Medicine, 1985 - 1988
Stanford University School of MedicineClass of 1985

Certifications & Licensure

IA State Medical License 1993 - 2025
CA State Medical License 1987 - 1990
American Board of Internal Medicine Internal Medicine

Clinical Trials

Vaccine Study for Surgically Resected Pancreatic Cancer Start of enrollment: 2007 Dec 01
Completed
Phase 2
Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer Start of enrollment: 2008 Jan 01
Terminated
Phase 2
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors Start of enrollment: 2008 Aug 01
Terminated
Phase 1
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer Start of enrollment: 2012 Oct 01
Completed
Phase 2
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma Start of enrollment: 2014 Jul 01
Completed
Phase 1, Phase 2
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer Start of enrollment: 2014 Aug 01
Completed
Phase 1, Phase 2
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors Start of enrollment: 2015 Oct 01
Completed
Phase 1
A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2016 Jul 01
Completed
Phase 1
A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma Start of enrollment: 2017 Dec 08
Terminated
Phase 2
Oral Bioavailability,and Food Effect Study and Single Ascending Dose PK Study in Healthy Male Volunteers Start of enrollment: 2017 Nov 21
Completed
Phase 1
Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers Start of enrollment: 2018 Mar 05
Completed
Early Phase 1
Join now to see all

Publications & Presentations

PubMed

38 citations
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.
Yousef Zakharia, Robert R. McWilliams, Olivier Rixe, Joseph J. Drabick, Montaser Shaheen, Kenneth F. Grossmann, Ravindra Kolhe, Rafal Pacholczyk, Ramses F. Sadek, Luci...> ;Journal for Immunotherapy of Cancer. 2021 Jun 11
19 citations
Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial.
Veronica Mariotti, Hyo S. Han, Roohi Ismail-Khan, Shou-Ching Tang, Patrick M. Dillon, Alberto J. Montero, Andrew Poklepovic, Susan A. Melin, Nuhad K. Ibrahim, Eugene P...> ;JAMA Oncology. 2021 Jan 1
36 citations
A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects with Borderline Resectable or Local...
D Brock Hewitt, Nicholas Nissen, Hassan Hatoum, Benjamin L. Musher, John Seng, Andrew L. Coveler, Raed Al-Rajabi, Charles J. Yeo, Benjamin E. Leiby, Joshua Banks, Lodo...> ;Annals of Surgery. 2020 Dec 22
7 citations
Combination Immunotherapy for High-Risk Resected and Metastatic Melanoma Patients
Adam I. Riker, Gabriela R. Rossi, Prerna Masih, L. C. Alsfeld, Fiona Denham, Lucinda Tennant, W. Jay Ramsey, Nicholas N. Vahanian, Charles J. Link> ;Ochsner Journal. 2014 Jun 6
1 citations
The Ebola vaccine underdog
Jon Cohen> ;Science. 2014 Oct 31
17 citations
Indoximod opposes the immunosuppressive effects mediated by IDO and TDO via modulation of AhR function and activation of mTORC1.
Erik L. Brincks, James Adams, Lifu Wang, Benjamin L. Turner, Agnieszka Marcinowicz, Jiyuan Ke, Michael Essmann, Lucía M Mautino, Clarissa Van Allen, Sanjeev Kumar, Nic...> ;Oncotarget. 2020 Jun 23
23 citations
Discovery of indoximod prodrugs and characterization of clinical candidate NLG802.
Sanjeev Kumar, Firoz Jaipuri, Jesse Waldo, Hima Potturi, Agnieszka Marcinowicz, James Adams, Clarissa Van Allen, Hong Zhuang, Nicholas N. Vahanian, Charles J. Link, Er...> ;European Journal of Medicinal Chemistry. 2020 Jul 15
5 citations
A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma.
Andrew W Hahn, Charles Drake, Samuel R Denmeade, Yousef Zakharia, Benjamin L Maughan, Eugene Kennedy, Charles Link Jr, Nicholas Vahanian, Hans Hammers, Neeraj Agarwal> ;The Oncologist. 2020 Feb 1
90 citations
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
Asha Nayak-Kapoor, Zhonglin Hao, Ramses F. Sadek, Robin Dobbins, Lisa Marshall, Nicholas N. Vahanian, W. Jay Ramsey, Eugene P. Kennedy, Mario R. Mautino, Charles J. Li...> ;Journal for Immunotherapy of Cancer. 2018 Jun 20
4 citations
Addition of αGal HyperAcute™ technology to recombinant avian influenza vaccines induces strong low-dose antibody responses.
Wenlan Alex Chen, Jinjin Zhang, Katie M. Hall, Carol B. Martin, Serguei Kisselev, Emily J Dasen, Nicholas N. Vahanian, Charles J. Link, Brian K. Martin> ;Plos One. 2017 Aug 7
69 citations
Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled,...
D. Gray Heppner, Tracy Kemp, Brian K. Martin, William Jay Ramsey, Richard A. Nichols, Emily J Dasen, Charles J. Link, Rituparna Das, Zhi Jin Xu, Eric A Sheldon, Teresa...> ;The Lancet. Infectious Diseases. 2017 Aug 1
269 citations
A Recombinant Vesicular Stomatitis Virus Ebola Vaccine — Preliminary Report
Jason A. Regules, John H. Beigel, Kristopher M. Paolino, Jocelyn Voell, Amy R. Castellano, Zonghui Hu, Paula Muñoz, James E. Moon, Richard C. Ruck, Jason W. Bennett, P...> ;The New England Journal of Medicine. 2017 Jan 26
101 citations
a phase i study of indoximod in patients with advanced malignancies
Hatem Soliman, Susan Minton, Hyo S. Han, Roohi Ismail-Khan, Anthony Neuger, Fatema Khambati, David Noyes, Richard Lush, Alberto Chiappori, John D. Roberts, Charles J. ...> ;Oncotarget. 2016 Mar 20
25 citations
Pancreatic cancer: Update on immunotherapies and algenpantucel-L
Kinsey A. McCormick, Andrew L. Coveler, Gabriela R. Rossi, Nicholas N. Vahanian, Charles J. Link, E. Gabriela Chiorean> ;Human Vaccines & Immunotherapeutics. 2016 Mar 3
18 citations
Algenpantucel-L immunotherapy in pancreatic adenocarcinoma.
Andrew Coveler, Gabriela R. Rossi, Nicholas N. Vahanian, Charles J. Link, E. Gabriela Chiorean> ;Immunotherapy. 2016 Jan 20
67 citations
Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick.
Lilin Lai, Richard J. Davey, Allison Beck, Yongxian Xu, Anthony F. Suffredini, Tara N. Palmore, Sarah Kabbani, Susan Rogers, Gary P. Kobinger, Judie B. Alimonti, Charl...> ;JAMA. 2015 Mar 24
126 citations
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
Hatem Soliman, Erica Jackson, Tony Neuger, Claire Dees, Donald R. Harvey, Hyo S. Han, Roohi Ismail-Khan, Susan Minton, Nicholas N. Vahanian, Charles J. Link, Daniel M....> ;Oncotarget. 2014 Aug 22
6 citations
U6 promoter-enhanced GlnUAG suppressor tRNA has higher suppression efficacy and can be stably expressed in 293 cells.
Ramesh Koukuntla, William Jay Ramsey, Won-Bin Young, Charles J. Link> ;The Journal of Gene Medicine. 2013 Feb 1
8 citations
Cellular immunotherapy study of prostate cancer patients and resulting IgG responses to peptide epitopes predicted from prostate tumor-associated autoantigens.
George P. Hemstreet, Gabriela R. Rossi, Vladimir M. Pisarev, Charles A. Enke, Laura Helfner, Ralph J. Hauke, Lucinda Tennant, William Jay Ramsey, Nicholas N. Vahanian,...> ;Journal of Immunotherapy. 2013 Jan 1
272 citations
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan
Richard Metz, Sonja Rust, James B. DuHadaway, Mario R. Mautino, David H. Munn, Nicholas N. Vahanian, Charles J. Link, George C. Prendergast> ;Oncoimmunology. 2012 Dec 1
Effect of cellular vaccination of prostate cancer patients on IgG responses to peptide epitopes predicted from prostate tumor-associated autoantigens.
Hemstreet GP, Pisarev VM, Enke CA, Hauke RJ, Rossi GR, Tennant L, Ramsey WJ, Vahanian NN, Link CJ> ;J. Clin. Oncol.. 2011-05-20
Combination immunotherapy for high-risk and advanced melanoma patients.
Riker AI, Vahanian NN, Link CJ, Tennant L, Ramsey WJ, Rossi GR, Alsfeld LC, Davila E, Harrison M> ;J. Clin. Oncol.. 2011-05-20
17 citations
Novel suspension cell-based vaccine production systems for Rift Valley fever virus-like particles.
Robert Barry Mandell, Ramesh Koukuntla, Laura J.K. Mogler, Andrea K. Carzoli, Michael R. Holbrook, Brian K. Martin, Nicholas N. Vahanian, Charles J. Link, Ramon Flick> ;Journal of Virological Methods. 2010 Nov 1
57 citations
A Replication-incompetent Rift Valley Fever Vaccine: Chimeric Virus-like Particles Protect Mice and Rats Against Lethal Challenge
Robert Barry Mandell, Ramesh Koukuntla, Laura J.K. Mogler, Andrea K. Carzoli, Alexander N. Freiberg, Michael R. Holbrook, Brian K. Martin, William R. Staplin, Nicholas...> ;Virology. 2010 Feb 5
The αGal HyperAcute(®) Technology: enhancing immunogenicity of antiviral vaccines by exploiting the natural αGal-mediated zoonotic blockade.
Mandell RB, Flick R, Staplin WR, Kaniewski LD, Carzoli AK, Manuszak RP, Wang J, Rossi GR, Vahanian NN, Link CJ> ;Zoonoses Public Health. 2009-08-01
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

CharlesJLinkJr.MDFACP

Dr. Link is on Doximity

Summary

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.